Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in European Heart Journal, adding:
“Just published in EHJ Cardiovascular Pharmacotherapy: API-CAT Study and extended anticoagulant treatment for CAT : a practice changing study
Question: What are the investigators’ anticoagulant treatment decisions for patients enrolled in the API-CAT trial following study treatment discontinuation, prior to trial unblinding?
Findings: In this analysis of the prospective randomized clinical trial that included 1766 adults, clinicians decided to discontinue treatment in 13.6% patients and to continue in 1260 (86.4%) (about 2/3 at full dose and 1/3 at reduced dose).
Perspective: In light of API-CAT, broader adoption of reduced-dose apixaban for extended anticoagulation is anticipated.
Systematically capturing clinicians’ anticoagulation decisions after completion of the planned treatment period in prospective studies is critical.
API-CAT Study: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | New England Journal of Medicine”
Title: API-CAT investigators’ decisions on anticoagulation following extended treatment for cancer-associated thrombosis: Clinical decisional uncertainty in extended anticoagulation for cancer-associated Thrombosis: the investigators’ view before practice-changing evidence from the API-CAT trial
Authors: Isabelle Mahé, Florent Happe, Manuel Monreal, Helia Robert-Ebadi, Philippe Debourdeau, Jean-Roch Fabreguettes, Sandrine Accassat, Patrick Mismetti, Philippe Girard, Silvy Laporte, Céline Chapelle
Find more posts featuring Isabelle Mahé on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?